Double-masked, randomized, phase 2 evaluation of abicipar pegol (an Anti-VEGF DARPin Therapeutic) in neovascular age-related macular degeneration

Journal of Ocular Pharmacology and Therapeutics

Volumn 34, Issue 10, 2018, Pages 700-709

  Callanan, David ^a   Kunimoto, Derek ^b   Maturi, Raj K ^c,d   Patel, Sunil S ^e   Staurenghi, Giovanni ^f   Wolf, Sebastian ^g   Cheetham, Janet K ^h   Hohman, Thomas C ^h   Kim, Kimmie ^h   López, Francisco J ^h   Schneider, Susan ^h  

^a TEXAS RETINA ASSOCIATES   (United States)

^b RETINAL CONSULTANTS OF ARIZONA   (United States)

^c MIDWEST EYE INSTITUTE   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e West Texas Retina   (United States)

^f UNIVERSITY OF MILAN   (Italy)

^g UNIVERSITY OF BERN   (Switzerland)

^h ALLERGAN INC   (United States)

Author keywords

abicipar pegol; age related macular degeneration; anti VEGF; choroidal neovascularization; optical coherence tomography; vascular endothelial growth factor

Indexed keywords

ABICIPAR PEGOL; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; FUSION PROTEIN; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; BEST CORRECTED VISUAL ACUITY; CENTRAL RETINAL THICKNESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; VISUAL IMPAIRMENT; WET MACULAR DEGENERATION; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DOUBLE BLIND PROCEDURE; INTRAVITREAL DRUG ADMINISTRATION; MACULAR DEGENERATION; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; PROCEDURES; RETINA; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; CHOROIDAL NEOVASCULARIZATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; RANIBIZUMAB; RECOMBINANT FUSION PROTEINS; RETINA; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 85058445979     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2018.0062     Document Type: Article

References (29)

1. Yonekawa, Y., and Kim, I.K. Clinical characteristics and current treatment of age-related macular degeneration. Cold Spring Harb. Perspect. Med. 5:a017178, 2015.
2. Friedman, D.S., O'Colmain, B.J., Muñoz, B., et al. The Eye Diseases Prevalence Research Group. Prevalence of agerelated macular degeneration in the United States. Arch. Ophthalmol. 122:564-572, 2004.
3. Ferris, F.L. 3rd, Wilkinson, C.P., Bird, A., et al. Clinical classification of age-related macular degeneration. Ophthalmology. 120:844-851, 2013.
4. Brown, D.M., Kaiser, P.K., Michels, M., et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 355:1432-1444, 2006.
5. Rosenfeld, P.J., Brown, D.M., Heier, J.S., et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355:1419-1431, 2006.
6. Fung, A.E., Lalwani, G.A., Rosenfeld, P.J., et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am. J. Ophthalmol. 143: 566-583, 2007.
7. Holz, F.G., Amoaku, W., Donate, J., et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: The SUSTAIN study. Ophthalmology. 118:663-671, 2011.
8. Singer, M.A., Awh, C.C., Sadda, S., et al. HORIZON: An open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 119:1175-1183, 2012.
9. Vazquez-Lombardi, R., Phan, T.G., Zimmermann, C., et al. Challenges and opportunities for non-antibody scaffold drugs. Drug Discov. Today. 20:1271-1283, 2015.
10. Pluückthun, A. Designed ankyrin repeat proteins (DARPins): Binding proteins for research, diagnostics, and therapy. Annu. Rev. Pharmacol. Toxicol. 55:489-511, 2015.
11. Eggel, A., Buschor, P., Baumann, M.J., et al. Inhibition of ongoing allergic reactions using a novel anti-IgE DARPin- Fc fusion protein. Allergy. 66:961-968, 2011.
12. Souied, E.H., Devin, F., Mauget-Fayüsse, M., et al. Treatment of exudative age-related macular degeneration with a designed ankyrin repeat protein that binds vascular endothelial growth factor: A phase I/II study. Am. J. Ophthalmol. 158:724-732, 2014.
13. Campochiaro, P.A., Channa, R., Berger, B.B., et al. Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: A phase I/II study. Am. J. Ophthalmol. 155: 697-704, 2013.
14. Papadopoulos, N., Martin, J., Ruan, Q., et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 15:171-185, 2012.
15. Krohne, T.U., Liu, Z., Holz, F.G., Meyer, C.H. Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am. J. Ophthalmol. 154: 682-686, 2012.
16. Age-Related Eye Disease Study Research Group. The Age- Related Eye Disease Study (AREDS): Design implications. AREDS report no. 1. Control Clin. Trials. 20:573-600, 1999.
17. Heier, J.S., Brown, D.M., Chong, V., et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 119:2537-2548, 2012.
18. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 308:81-106, 1994. Erratum in: BMJ 308: 1540, 1994.
19. Chang, T.S., Bressler, N.M., Fine, J.T., et al. MARINA Study Group. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: Results of a randomized clinical trial. Arch. Ophthalmol. 125:1460-1469, 2007.
20. Bressler, N.M., Chang, T.S., Suñer, I.J., et al. MARINA and ANCHOR Research Groups. Vision-related function after ranibizumab treatment by better- or worse-seeing eye: Clinical trial results from MARINA and ANCHOR. Ophthalmology. 117:747-756.e4, 2010.
21. Holekamp, N.M., Liu, Y., Yeh, W.S., et al. Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration. Am. J. Ophthalmol. 157:825-833, 2014.
22. Kiss, C.G., Geitzenauer, W., Simader, C., et al. Evaluation of ranibizumab-induced changes in high-resolution optical coherence tomographic retinal morphology and their impact on visual function. Invest. Ophthalmol. Vis. Sci. 50: 2376-2383, 2009.
23. Golbaz, I., Ahlers, C., Stock, G., et al. Quantification of the therapeutic response of intraretinal, subretinal, and subpigment epithelial compartments in exudative AMD during anti-VEGF therapy. Invest. Ophthalmol. Vis. Sci. 52:1599-1605, 2011.
24. Sulzbacher, F., Roberts, P., Munk, M.R., et al. Relationship of retinal morphology and retinal sensitivity in the treatment of neovascular age-related macular degeneration using aflibercept. Invest. Ophthalmol. Vis. Sci. 56:1158-1167, 2015.
25. Jaffe, G.J., Martin, D.F., Toth, C.A., et al. Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 120:1860-1870, 2013.
26. Waldstein, S.M., Simader, C., Staurenghi, G., et al. Morphology and visual acuity in aflibercept and ranibizumab therapy for neovascular age-related macular degeneration in the VIEW trials. Ophthalmology. 123:1521-1529, 2016.
27. Ritter, M., Simader, C., Bolz, M., et al. Intraretinal cysts are the most relevant prognostic biomarker in neovascular agerelated macular degeneration independent of the therapeutic strategy. Br. J. Ophthalmol. 98:1629-1635, 2014.
28. Schmidt-Erfurth, U., Waldstein, S.M., Deak, G.G., et al. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration. Ophthalmology. 122:822-832, 2015.
29. Avery R.L., Castellarin A.A., Steinle N.C., et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br. J. Ophthalmol. 98:1636-1641, 2014.